CURAM Centre for Research in Medical Devices

curamdevices.ie

CÚRAM is a multidisciplinary research centre advancing R&D in the medical device sector. Supported by Science Foundation Ireland and industry partners, CÚRAM enhances Ireland’s standing as a major hub for the global medical devices industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

SS&C PARTNERS WITH XCENTUATE TO SUPPORT CUSTOMER DIGITAL TRANSFORMATION JOURNEYS

SS&C | June 23, 2022

news image

SS&C Technologies Holdings, Inc. announced a new partnership in the EMEA and APAC regions with Xcentuate, an award-winning international provider of digital productivity and performance solutions to the financial services, agricultural, pharma and public sectors. The partnership follows SS&C's recent acquisition of Blue Prism, the leading Robotic Process Automation provider, further demonstrating its commitment to the intelligent automation solutions market. Xcentuate,...

Read More

Pharma Tech

ANTENGENE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH BEIGENE TO EVALUATE SELINEXOR IN COMBINATION WITH TISLELIZUMAB IN T AND NK-CELL LYMPHOMA

Antengene Corporation Limited | June 27, 2022

news image

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizum...

Read More

HITGEN AND MORPHIC THERAPEUTIC EXTEND DRUG DISCOVERY RESEARCH COLLABORATION TO IDENTIFY SMALL MOLECULE LEADS AGAINST TARGETS

HitGen Inc., Morphic Therapeutic | July 06, 2020

news image

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compoun...

Read More

Business Insights

ARS PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM WITH ADDITION OF PHARMACEUTICAL COMMERCIALIZATION VETERANS

ARS Pharmaceuticals, Inc. | February 10, 2022

news image

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive vice president, commercial strategy and Daniel Relovsky as senior vice president, sales and marketing. Mr. Kaplan and Mr. Relovsky, accomplished industry veterans with proven track r...

Read More
news image

Business Insights

SS&C PARTNERS WITH XCENTUATE TO SUPPORT CUSTOMER DIGITAL TRANSFORMATION JOURNEYS

SS&C | June 23, 2022

SS&C Technologies Holdings, Inc. announced a new partnership in the EMEA and APAC regions with Xcentuate, an award-winning international provider of digital productivity and performance solutions to the financial services, agricultural, pharma and public sectors. The partnership follows SS&C's recent acquisition of Blue Prism, the leading Robotic Process Automation provider, further demonstrating its commitment to the intelligent automation solutions market. Xcentuate,...

Read More
news image

Pharma Tech

ANTENGENE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH BEIGENE TO EVALUATE SELINEXOR IN COMBINATION WITH TISLELIZUMAB IN T AND NK-CELL LYMPHOMA

Antengene Corporation Limited | June 27, 2022

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizum...

Read More
news image

HITGEN AND MORPHIC THERAPEUTIC EXTEND DRUG DISCOVERY RESEARCH COLLABORATION TO IDENTIFY SMALL MOLECULE LEADS AGAINST TARGETS

HitGen Inc., Morphic Therapeutic | July 06, 2020

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compoun...

Read More
news image

Business Insights

ARS PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM WITH ADDITION OF PHARMACEUTICAL COMMERCIALIZATION VETERANS

ARS Pharmaceuticals, Inc. | February 10, 2022

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive vice president, commercial strategy and Daniel Relovsky as senior vice president, sales and marketing. Mr. Kaplan and Mr. Relovsky, accomplished industry veterans with proven track r...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us